Læknablaðið - 15.06.2007, Page 25

FRÆÐIGREIN / GEISLAGERLABÓLGA
44. Sparks RA, Purrier BG, Watt PJ, Elstein M. Bacteriological
colonisation of uterine cavity: role of tailed intrauterine
contraceptive device. Brit Med J Clin Res Ed 1981; 282:1189-
91.
45. Mishell DR,Jr.,Moyer DL.Association ofpelvic inflammatory
disease with the intrauterine device. Clin Obstet Gynecol 1969;
12:179-97.
46. Mishell DR, Jr., Bell JH, Good RG, Moyer DL. The
intrauterine device: a bacteriologic study of the endometrial
cavity. Am J Obstet Gynecol 1966; 96:119-26.
47. Curtis EM, Pine L. Actinomyces in the vaginas of women with
and without intrauterine contraceptive devices. Am J Obstet
Gynecol 1981; 140:880-4.
48. Hager WD, Douglas B, Majmudar B, Naib ZM, Williams OJ,
Ramsey C, et al. Pelvic colonization with Actinomyces in
women using intrauterine contraceptive devices. Am J Obstet
Gynecol 1979; 135:680-4.
49. Aubert JM, Gobeaux-Castadot MJ, Boria MC. Actinomyces in
the endometrium of IUD users. Contraception 1980; 21: 577-
83.
50. Schmidt WA, Bedrossian CW, AIi V, Webb JA, Bastian FO.
Actinomycins and intrauterine contraceptive devices: the
clinicopathologic study. Diagn Gynecol Obstet 1980; 2: 165-
77.
51. Fiorino AS. Intrauterine contraceptive device-associated
actinomycotic abscess and Actinomyces detection on cervical
smear. Obstet Gynecol 1996; 87:142-9.
52. Marella VK, Hakimian O, Wise GJ, Silver DA. Pelvic
actinomycosis. Urologic perspective. Int Braz J Urol 2004; 30:
367-76.
53. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the
present and predicting the future. Future Oncology 2005; 1:
37-50.
54. Carlson K. Screening for ovarian cancer. Uptodate.com; 2006.
55. Bast RC, Jr., Badgwell D, Lu Z, Marquez R, Rosen D, Liu J,
et al. New tumor markers: CA125 and beyond. Int J Gynecol
Cancer 2005; 15 Suppl 3:274-81.
56. Meden H, Fattahi-Meibodi A. CA 125 in benign gynecological
conditions. Int J Biol Markers 1998; 13:231-7.
57. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in
the staging and follow-up of patients with colorectal cancer.
Cancer Invest 2005; 23:338-51.
58. van der Schouw YT, Verbeek AL, Wobbes T, Segers MF,
Thomas CM. Comparison of four serum tumour markers in
the diagnosis of colorectal carcinoma. Brit J Cancer 1992; 66:
148-54.
59. Strom BL, Maislin G, West SL, Atkinson B, Herlyn M, Saul S,
et al. Serum CEA and CA 19-9: potential future diagnostic or
screening tests for gallbladder cancer? Int J Cancer 1990; 45:
821-4.
60. Michl P, Pauls S, GressT. Evidence-based diagnosis and staging
of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;
20:227-51.
61. Bast RC, Jr., Ravdin P, Hayes DF, Bates S, Fritsche H, Jr.,
Jessup JM, et al. 2000 update of recommendations for the
use of tumor markers in breast and colorectal cancer: clinical
practice guidelines of the American Society of Clinical
OncoIogy.[erratum appears in J Clin Oncol 2001 Nov
l;19(21):4185-8]. J Clin Oncol 2001; 19:1865-78.
62. Sumer Y, Yilmaz B, Emre B, Ugur C. Abdominal mass
secondary to actinomyces infection: an unusual presentation
and its treatment. J Postgrad Med 2004; 50:115-7.
Læknablaðið 2007/93 485